 Thirty-two patients will be treated with nivolumab 240 mg flat dose, week 1 and week 3, twice in total as a single agent OR the combination of ipilimumab 1 mgkg nivolumab 240mg flat dose in week 1, and nivolumab 240mg flat dose in week 3, neoadjuvant to SOC surgery with or without adjuvant CRT. 